Breaks Categories: News

WednesdayAug 20, 2025 3:03 pm

BioMedNewsBreaks — BioAdaptives, Inc. (OTCMKTS: BDPT) Receives WADA-Compliant Certification for MyndMed(TM) From TruShield(TM) 

BioAdaptives (OTCMKTS: BDPT), a developer of natural health and performance supplements, said its nootropic formula MyndMed(TM) was certified clean by TruShield(TM) Laboratory Services following testing for World Anti-Doping Agency compliance. TruShield, whose protocols are trusted by professional sports organizations including the UFC(R), confirmed MyndMed contains no banned substances and meets safety standards for competitive athletes. BioAdaptives said the clearance supports integration of MyndMed into the UFC’s approved supplement pool, providing fighters with cognitive performance, focus and reaction-time support without risk of anti-doping violations. To view the full press release, visit https://ibn.fm/4b4Xj About BioAdaptives, Inc. BioAdaptives, Inc. develops and markets science-based…

Continue Reading

WednesdayAug 20, 2025 11:32 am

BioMedNewsBreaks — Calidi Biotherapeutics Inc. (NYSE American: CLDI) Prices $6 Million Public Offering 

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted therapies to deliver genetic medicines, announced the pricing of an underwritten public offering for gross proceeds of $6 million before expenses. The offering includes about 1.47 million common stock units priced at $2.00 each and about 1.53 million pre-funded warrant units priced at $1.999 each, both paired with Series I warrants exercisable at $2.00 per share for five years. Ladenburg Thalmann is serving as sole book-running manager with Laidlaw & Company (U.K.) Ltd. as co-manager. To view the full press release, visit https://ibn.fm/SN44B About Calidi Biotherapeutics Calidi Biotherapeutics (NYSE…

Continue Reading

TuesdayAug 19, 2025 10:50 am

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Launches BreastCT.com to Advance Awareness of Dedicated Breast CT Technology

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company commercializing imaging-based products for more accurate breast cancer screening, diagnoses, and treatment, announced the launch of BreastCT.com, a new online platform supporting its awareness initiatives. The site serves as a central educational resource on dedicated breast CT technology and Izotropic’s IzoView Breast CT Imaging System, emphasizing its potential to address challenges in detecting cancer in the 50% of women with dense breast tissue. With IzoView’s engineering complete, the platform will evolve with the Company through clinical study preparation, U.S. and global regulatory phases, and ongoing awareness programs leading to…

Continue Reading

MondayAug 18, 2025 10:55 am

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20

Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community. To view the full article, visit https://ibn.fm/dhj3J About Nutriband Inc. We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA(TM) abuse-deterrent technology. AVERSA(TM) technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse…

Continue Reading

MondayAug 18, 2025 10:40 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q2 2025 Results, Highlights Progress Across Lead Programs and Strategic Investment

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, reported financial results for the quarter ended June 30, 2025, and provided a corporate update. The Company highlighted progress in all three lead programs, including expanded FDA Fast Track designation for NRX-100 in treating suicidal depression, filing of multiple regulatory documents, and advancement of the NRX-101 NDA. A strategic investor group led by B Group Capital has committed capital through a purchase of restricted common stock with a one-year lockup and no dilutive mechanisms. The capital is expected to support the Company through key regulatory milestones and help scale HOPE Therapeutics and…

Continue Reading

MondayAug 18, 2025 9:24 am

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Awarded FDA Orphan Drug Designation for Dusquetide in Behçet’s Disease

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases, announced the U.S. FDA has granted orphan drug designation to dusquetide, the active ingredient in SGX945, for treatment of Behçet's Disease. The designation follows a review of recent Phase 2a clinical results demonstrating biological efficacy and safety in patients. To view the full press release, visit https://ibn.fm/Up5sU About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) (SGX301 or…

Continue Reading

FridayAug 15, 2025 10:35 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q2 2025 Results, Advances TPI 287 Toward Phase 2 GBM Trial

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for cancers in the brain and central nervous system, reported a Q2 2025 net loss of $2.4 million, slightly improved from $2.5 million in Q2 2024, driven by reduced Berubicin trial costs. R&D expenses rose to $1.2 million from $1.1 million on preparation for a TPI 287 trial, while G&A fell to $1.2 million from $1.4 million on lower legal, travel and stock-based compensation costs. The Company ended the quarter with $12.1 million in cash, sufficient to fund operations into the second half of 2026. CEO John Climaco said CNS is…

Continue Reading

ThursdayAug 14, 2025 3:38 pm

BioMedNewsBreaks — NextPlat Corp (NASDAQ: NXPL) Narrows Q2 Loss 66% as E-Commerce Growth Offsets Healthcare Headwinds

NextPlat (NASDAQ: NXPL, NXPLW), a global consumer products and services company in healthcare and technology, reported Q2 2025 revenue of $13.2 million versus $17.0 million a year ago, reflecting strong e-commerce growth offset by declines in healthcare operations from lower prescription volumes and reduced 340B contract revenue. Gross margin fell to 21.8% from 34.5% on mix shifts and industry drug price pressures. Operating expenses dropped to $4.7 million from $16.8 million on the absence of prior-year non-recurring charges and cost-cutting measures, producing a net loss of $1.8 million, or ($0.07) per share, compared to a $5.3 million loss last year.…

Continue Reading

ThursdayAug 14, 2025 11:00 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Webull Financial Biotech/MedTech Webinar Series

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharma company developing novel treatments for primary and metastatic cancers in the brain and central nervous system, announced it will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, taking place virtually Aug. 19–21, 2025. To view the full press release, visit https://ibn.fm/ctTvf About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's drug candidate TPI 287 is an abeotaxane, which stabilizes microtubules and inhibits cell division, causing apoptosis…

Continue Reading

ThursdayAug 14, 2025 10:15 am

BioMedNewsBreaks – Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results, Targets Year-End NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN), a late clinical-stage biopharma company developing treatments for neurodegenerative diseases, reported Q2 2025 results and said it has sufficient cash runway into Q1 2026. The company plans to meet with the FDA this quarter to review survival data for lead candidate CNM-Au8 in amyotrophic lateral sclerosis (ALS) and is preparing analyses of NIH-sponsored Expanded Access Program neurofilament light biomarker data, expected in Q4. These steps are intended to support a potential New Drug Application submission under the FDA’s accelerated approval pathway for ALS by year-end 2025. Management said its focus remains on delivering an impactful therapy to the…

Continue Reading